Synovial sarcoma is a rare type of cancer that requires specialized treatment to manage symptoms and slow its growth. This cancer affects soft tissues like muscles, ligaments, and tendons, often appearing near large joints. The journey toward healing depends on many factors, including how early the disease is found, where the tumor is located, and whether it has spread to other parts of the body. Treatment approaches include standard options approved by medical organizations, as well as innovative therapies being tested in clinical trials that offer new hope for people living with this challenging disease.

Understanding Treatment Goals for Synovial Sarcoma

When someone receives a diagnosis of synovial sarcoma, the main goal of treatment is to remove or control the cancer while preserving as much normal function as possible. This means trying to save limbs, reduce pain, prevent the cancer from spreading, and help people maintain their quality of life. Because synovial sarcoma grows slowly and may not cause pain at first, it can develop for up to two years before being detected, which sometimes makes treatment more complicated.^[1]

The approach to treating synovial sarcoma depends heavily on the stage of the disease when it is discovered. If the tumor is found early and has not spread, doctors can often remove it completely with surgery, which gives patients a better chance of recovery. However, when the cancer has already spread to other parts of the body, which happens in about one-third of cases, treatment becomes more complex and may involve multiple approaches working together.^[3]

Treatment decisions also take into account the size and location of the tumor, the patient’s age and overall health, and whether the tumor can be completely removed through surgery. Doctors consider all these factors when creating a personalized treatment plan. The medical team typically includes surgeons, oncologists who specialize in cancer treatment, radiation specialists, and physical therapists who all work together to provide comprehensive care.^[4]

It is important to understand that synovial sarcoma is a very aggressive cancer with a high potential for metastasis, which means spreading to other parts of the body. This characteristic makes early treatment and careful monitoring essential. Even after successful treatment, the cancer can sometimes return, so ongoing follow-up care is a crucial part of the treatment journey.^[4]

Standard Treatment Methods

The cornerstone of treating synovial sarcoma is surgical removal of the tumor. Surgery remains the most important treatment option because it offers the best chance of eliminating the cancer if it can be completely removed. During surgery, the goal is to take out the tumor along with a margin of healthy tissue around it, usually between one and three centimeters, to ensure no cancer cells are left behind. This type of surgery is called wide resection with margins.^[5][12]

Many years ago, removing an arm or leg through amputation was often necessary to treat synovial sarcoma in the limbs. However, medical advances have made it possible to perform limb-sparing surgery in most cases. This type of surgery removes the tumor while preserving the limb, though it may involve removing entire muscles or muscle groups. The success of limb-sparing surgery depends on factors like the tumor’s size and location. If doctors worry that cancer has spread to nearby lymph nodes, which are small structures that filter body fluids, these may also be removed during surgery.^[1][5]

Radiation therapy is another standard treatment for synovial sarcoma. This treatment uses powerful energy beams to kill cancer cells. Radiation can be given before surgery to shrink the tumor and make it easier to remove completely. It can also be used after surgery to destroy any cancer cells that might remain in the body. The radiation is carefully directed at the tumor site while you lie on a table as a machine moves around you.^[9]

Using radiation therapy before surgery, called neoadjuvant radiation, can make a successful operation more likely by reducing the tumor size. After surgery, adjuvant radiation helps lower the chances of the cancer returning. However, radiation to the area can cause healthy tissues to become less stretchy over time, which may lead to tightness and discomfort in the treated area.^[9]

Chemotherapy, which uses drugs to kill cancer cells, is the third main treatment approach. The role of chemotherapy in treating synovial sarcoma has been controversial, especially in adults. Some studies have shown that it can improve survival rates in certain patients, while others have not found clear benefits. Despite this debate, chemotherapy is regularly used in children and is often recommended for adults with high-risk tumors, particularly those larger than five centimeters.^[4][12]

The chemotherapy drugs most commonly used for synovial sarcoma include doxorubicin and ifosfamide. Doxorubicin may be given through continuous infusion over three days at a dose of 75 milligrams per square meter of body surface. Ifosfamide is typically given at 2.5 grams per square meter daily for four days. Sometimes these drugs are combined with cyclophosphamide. Another combination uses docetaxel with gemcitabine.^[12]

A retrospective study of 271 patients with synovial sarcoma found that those who received adjuvant chemotherapy had a five-year metastasis-free survival rate of 60 percent, compared to 48 percent for those who did not receive chemotherapy. This suggests that chemotherapy after surgery may help prevent the cancer from spreading, especially in patients with high-risk features.^[12]

Other chemotherapy drugs used as second-line treatments, meaning they are tried when first-line drugs do not work, include pazopanib, trabectedin, eribulin, dacarbazine, and etoposide. However, studies have shown that the response rate to second-line chemotherapy is generally poor, at around nine percent, which highlights the need for better treatment options.^[12]

Chemotherapy can cause various side effects because it affects rapidly dividing cells throughout the body, not just cancer cells. Common side effects include nausea, vomiting, diarrhea, fatigue, hair loss, and a decrease in blood cell counts that can make patients more vulnerable to infections. To help the bone marrow recover, doctors may prescribe granulocyte colony-stimulating factor, or G-CSF, which stimulates the production of white blood cells.^[12]

The duration of treatment varies depending on the individual situation. Surgery is typically a one-time event, though recovery and rehabilitation can take many months. Radiation therapy is usually given five days a week for several weeks. Chemotherapy is typically given in cycles, with periods of treatment followed by rest periods to allow the body to recover. The total duration of chemotherapy treatment can range from several months to longer, depending on how well the cancer responds.^[5]

Innovative Therapies Being Tested in Clinical Trials

Because standard treatments for synovial sarcoma have limitations, researchers are actively working to develop new therapies through clinical trials. These trials test innovative approaches that may offer better results or fewer side effects than current treatments. Participating in a clinical trial gives patients access to cutting-edge therapies while helping scientists advance medical knowledge.

One promising area of research involves immunotherapy, which harnesses the body’s own immune system to fight cancer. A particularly exciting development is TECELRA, a genetically modified autologous T cell immunotherapy. This treatment is different from other cancer medicines because it is made from the patient’s own white blood cells, which are modified in a laboratory to recognize and attack synovial sarcoma cells specifically.^[3]

TECELRA works by targeting a specific feature found in synovial sarcoma cells. Healthcare providers perform tests to determine if a patient’s cancer has the right characteristics for this treatment to work. The therapy was approved based on patient response data, though additional studies are ongoing to confirm its clinical benefit. This type of personalized medicine represents a significant advance because it is tailored to the unique genetic features of the patient’s cancer.^[3]

Another innovative approach involves targeting a protein called WDR5. Researchers at Duke University School of Medicine discovered that this protein interacts with the abnormal SS18:SSX fusion protein found in nearly all synovial sarcoma cases. When scientists used a small molecule called MS67 to degrade WDR5 in laboratory studies, it suppressed the cancer-promoting activities of the fusion protein. This method also activated p53, a protein that suppresses cancer growth.^[14]

MS67 belongs to a class of drugs called proteolysis targeting chimeras, or PROTACs. These drugs work by causing specific proteins to be broken down inside cells. At least a dozen drugs in this class are currently in clinical trials for several types of cancer. Targeting WDR5 with PROTAC compounds shows promise specifically for synovial sarcomas that have the SS18:SSX fusion, which includes the vast majority of cases.^[14]

Studies in cell lines and in mice have shown that degrading WDR5 can effectively fight synovial sarcoma. Researchers hope to partner with clinical researchers and pharmaceutical companies to bring this strategy to human trials. The work was funded by the National Institutes of Health and presented at the 2025 American Association for Cancer Research conference.^[14]

Researchers are also exploring monoclonal antibodies as potential treatments. Studies have shown promising results using a murine monoclonal antibody that attacks a cell-surface receptor called FZD10, which is present in synovial sarcoma cells but absent in normal organs. While clinical applications of these antibodies are not yet available, they represent an exciting area of ongoing research.^[12]

Another innovative technique being investigated is an SYT-SSX-derived peptide vaccine. This approach aims to train the immune system to recognize and attack cells containing the abnormal fusion protein characteristic of synovial sarcoma. While still in early research stages, vaccine-based therapies could potentially offer a targeted way to prevent cancer recurrence after initial treatment.^[12]

Clinical trials for synovial sarcoma are being conducted in various locations, including the United States, Europe, and other regions worldwide. Eligibility for trials depends on many factors, including the stage of disease, previous treatments received, genetic characteristics of the tumor, and the patient’s overall health. Patients interested in clinical trials should discuss options with their oncology team, who can help determine which trials might be appropriate.^[4]

Some trials focus on patients with metastatic disease who have already received standard chemotherapy. For example, studies have compared various second-line regimens to determine which might work better. Other trials test combinations of existing drugs in new ways, such as combining topotecan with carboplatin for stage IV sarcomas.^[12]

Preliminary results from some clinical trials have shown improvements in clinical parameters, symptom reduction, and positive safety profiles for certain new treatments. However, it is important to understand that being in a clinical trial does not guarantee better outcomes than standard treatment, and new treatments may have unknown side effects. The decision to participate should be made carefully after discussing all risks and benefits with your medical team.

Most common treatment methods

• Surgery
  • Wide resection with margins removes the tumor along with one to three centimeters of surrounding healthy tissue
  • Limb-sparing surgery preserves the arm or leg while removing the tumor, though it may involve removing entire muscles or muscle groups
  • Amputation is rarely necessary today due to advances in surgical techniques
  • Lymph nodes may be removed if doctors suspect the cancer has spread to them
  • The goal is to achieve microscopic negative margins, meaning no cancer cells are visible at the edges of removed tissue
• Radiation Therapy
  • Neoadjuvant radiation before surgery can shrink tumors and make complete removal more likely
  • Adjuvant radiation after surgery destroys remaining cancer cells and reduces recurrence risk
  • Perioperative radiotherapy is used alongside surgery as a cornerstone of treatment
  • Treatment typically involves daily sessions over several weeks
  • Energy beams are precisely directed at the tumor site while protecting surrounding tissues
• Chemotherapy
  • Doxorubicin is given through continuous infusion, often at 75 mg/m² over three days
  • Ifosfamide is typically administered at 2.5 g/m² daily for four days
  • Combination therapy may include doxorubicin with ifosfamide or cyclophosphamide
  • Docetaxel combined with gemcitabine is used in some treatment protocols
  • Second-line options include pazopanib, trabectedin, eribulin, and dacarbazine
  • Granulocyte colony-stimulating factor (G-CSF) may be given to support bone marrow recovery
  • Chemotherapy is particularly recommended for tumors larger than 5 cm
• Immunotherapy
  • TECELRA is a genetically modified autologous T cell immunotherapy made from the patient’s own white blood cells
  • This treatment is modified to recognize and attack synovial sarcoma cells specifically
  • Healthcare providers perform tests to determine if patients are eligible for this therapy
  • It is approved for use when other treatments have not worked
• Targeted Therapy
  • Research focuses on PROTAC compounds like MS67 that degrade the WDR5 protein
  • Monoclonal antibodies targeting FZD10 receptor are being studied in laboratory settings
  • Treatments aim to disrupt the SS18:SSX fusion protein found in most synovial sarcomas
  • These therapies are designed to activate cancer-suppressing proteins like p53
• Vaccine Therapy
  • SYT-SSX-derived peptide vaccines are being investigated
  • These aim to train the immune system to recognize cancer cells
  • Potential use for preventing recurrence after initial treatment
• Rehabilitation
  • Physical therapy is essential after limb-sparing surgery or amputation
  • Exercise programs help gradually restore movement and strength
  • Recovery can take many months, with some patients achieving comfort within a year
  • Therapists create personalized programs based on the surgery performed and body area affected